Standard-risk rel/ref multiple myeloma patients with benefit from earlier treatment with cilta-cel, rather than waiting for later lines of therapy.

Mechelen, Belgium; December 8, 2025, 07:30 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announced new and updated Phase 2 data from the ongoing ATALANTA-1 study with its CD19 CAR T-cell therapy ...

Inaugural Members of the Akadeum CDMO Alliance: ElevateBio (R) and Charles River. Akadeum has collaborated with both CDMOs, establishing strong data sets demonstrating reduced impurities and high ...

It’s the stuff of a science fiction wellness clinic: blood drawn from the body, “rinsed” and “filtered,” then returned, with ...

Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in ...

High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell the ...

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression- and treatment-free following a single infusion as early as second line1 ...

People who search for INUSpheresis are usually already dealing with complex, long lasting illness. Many live with long COVID, ...

Between this and washing his blood - how does he get anything done?

Genetix Biotherapeutics Inc. today announced their participation in the American Society of Hematology's (ASH) exclusive press program ahead of the 67th ASH annual meeting in Orlando, Florida ...

Amicus™ high collection efficiency yields multiple products per donor for the lowest-cost platelet production. It is designed to adapt to the requirements of different collection settings. Let our ...